Phase 3 Polypoidal Choroidal Vasculopathy Clinical Trials
3 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–3 of 3 trials
Recruiting
Phase 3
Safety and Efficacy Evaluation of SMZ1 With Ranibizumab in Patients With Neovascular Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
Neovascular (Wet) Age-related Macular Degeneration Without Polypoidal Choroidal Vasculopathy
SANGMYUNG innovation266 enrolled1 locationNCT07695207
Recruiting
Phase 3
Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
Age-Related Macular DegenerationPolypoidal Choroidal Vasculopathy (PCV)
Yeungnam University College of Medicine50 enrolled1 locationNCT07461441
Recruiting
Phase 3
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
Polypoidal Choroidal VasculopathyPolypoidal Choroidal Vasculopathy (PCV)
Yeungnam University College of Medicine50 enrolled1 locationNCT07389980